Abstrakti
| Alkuperäiskieli | Englanti |
|---|---|
| Artikkeli | 547 |
| Julkaisu | Scientific Reports |
| Vuosikerta | 13 |
| Numero | 1 |
| DOI - pysyväislinkit | |
| Tila | Julkaistu - jouluk. 2023 |
| OKM-julkaisutyyppi | A1 Julkaistu artikkeli, soviteltu |
Rahoitus
The work has been partially supported by the H2020 project EVO-NANO (European Union’s Horizon 2020 research and innovation programme grant agreement No. 800983) and the EMJMD master’s programme in Engineering of Data-Intensive Intelligent Software Systems (EDISS—European Union’s Education, Audiovisual and Culture Executive Agency grant number 619819). We would like to express our gratitude to Marina Kovacevic at the University of Novi Sad, Otto Lindfors, and Victor-Bogdan Popescu at Åbo Akademi University for their help with several concepts. Additionally, we are thankful to CSC—IT Center for Science, Finland, for the computational resources.
Sormenjälki
Sukella tutkimusaiheisiin 'Predicting efficacy of drug-carrier nanoparticle designs for cancer treatment: a machine learning-based solution'. Ne muodostavat yhdessä ainutlaatuisen sormenjäljen.-
EDISS: EMJMD Programme on the Engineering of Data-intensive Intelligent Software Systems
Lafond, S. (Vastuullinen tutkija), Azimi Rashti, S. (Vastuullinen tutkija), Lilius, J. (CoPI), Strömborg, M. (Koordinaattori) & Iancu, B. (CoI)
Education, Audiovisual and Culture Executive Agency - European Commission
01/09/20 → 31/08/26
Projekti: EU
-
EVO-NANO: Evolvable platform for designing cancer treatment strategies using nanoparticles
Lafond, S. (Vastuullinen tutkija) & Azimi Rashti, S. (CoI)
01/10/18 → 31/03/22
Projekti: EU
Viittausmuodot
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver